Asthma exacerbation associated with COVID-19 pneumonia

Dear Editor,

Coronavirus (CoV) is a positive-sense single-stranded RNA virus, comprising four subgroups: α, β, γ, and δ. Alpha-CoVs, such as human CoV 229E (HCoV-229E) and HCoV-NL63, cause upper respiratory tract inflammation and can trigger asthma exacerbation. In contrast, severe acute respiratory syndrome-CoV-2 (SARS-CoV-2), SARS-CoV, and Middle East respiratory syndrome-CoV (MERS-CoV) are β-CoVs that target epithelial cells in the upper and lower airways. SARS-CoV-2 is the etiological agent for CoV disease (COVID-19), which manifests as fever, olfactory dysfunction, pneumonia, and in some cases, acute respiratory distress syndrome (ARDS). The COVID-19 outbreak began in Wuhan, China, and has been rapidly spreading worldwide. COVID-19 tends to be severe in patients with comorbid conditions, such as diabetes and chronic obstructive pulmonary disease. The risk of severe COVID-19 may be elevated in patients with asthma, especially with non-allergic asthma, however, it remains unclear whether asthmatic patients are susceptible to SARS-CoV-2 infection. Information is also limited on whether COVID-19 can cause asthma exacerbation and on treatment of asthma exacerbation accompanied by COVID-19. Here, we report a case of exacerbation of previously well-controlled asthma with the onset of COVID-19.

A 48-year-old woman with a history of asthma but no previous history of cigarette smoking was admitted to the hospital because of fever, wheezing, and dyspnea. She developed asthma at 34 years, which had been well-controlled under a combined treatment with inhaled corticosteroids, long-acting β-agonists, and a leukotriene receptor antagonist, accompanied by peripheral blood eosinophilia (618 cells/μL), but not by allergic sensitization or airflow limitation. Four days before admission, she had experienced fever and malaise, followed by sore throat and non-productive cough. On examination by a physician, she had a body temperature of 37.7 °C, percutaneous oxygen saturation (SpO2) of 98% on room air, and clear chest. Reverse transcriptase-polymerase chain reaction (RT-PCR) for SARS-CoV-2 was positive in a sample obtained from the nasopharynx, but influenza antigen tested negative. On admission, she had a body temperature of 37.7 °C, SpO2 of 86% on room air, and wheezing in the bilateral lung fields. No heart murmur or edema was observed. Blood tests revealed a peripheral blood leukocyte count of 8000/μL, with 72.6% neutrophils, 16.9% lymphocytes, and 0.6% eosinophils, and serum C-reactive protein level of 1.43 mg/dL. Chest radiography revealed mild opacities in the bilateral lungs (Fig. 1A), and thoracic computed tomography showed multifocal ground glass opacities in the bilateral lungs, and bronchial wall thickening (Fig. 1B, C). She was diagnosed with asthma exacerbation and COVID-19 pneumonia.

In addition to oxygen supplementation, inhalation of short-acting β agonists with a pressurized metered-dose inhaler to minimize the risk of aerosolization and infusion of methylprednisolone 160 mg/day were initiated. Inhalation of ciclesonide 1200 mg/day, oral favipiravir 1600 mg/day for 10 days, and infusion of nafamostat mesylate 250 mg/day for 8 days were administered for the treatment of COVID-19. Wheezes disappeared within 7 days; methylprednisolone administration and oxygen supplementation were terminated on days 5 and 10, respectively. RT-PCR result for SARS-CoV-2 was negative on day 21 after admission. Ground glass opacities and bronchial wall thickening had mostly disappeared (Fig. 1D, E).

To the best of our knowledge, there is only one case series of asthma exacerbation accompanied by SARS-CoV-2 infection.
Treatment with systemic corticosteroids could successfully control asthmatic symptoms and hypoxemia, with minor impacts on the eradication of the virus.

Rhinovirus and respiratory syncytial virus (RSV) are the major pathogens associated with asthma exacerbation; however, there have been several reports of the presence of α-CoV in the upper airways during asthma exacerbation. Furthermore, an experimental infection with HCoV-229E caused wheezing, chest tightness, and shortness of breath in viral wheezers but not in healthy subjects. However, data are limited on whether β-CoV infection can cause asthma exacerbation. There have been no reports on whether the administration of systemic corticosteroids delayed viral clearance in MERS-CoV cases. In the present case, the virus was cleared 25 days after fever onset, which is slightly prolonged compared with the median period of SARS-CoV-2 clearance previously reported. In the present case, the virus was cleared 25 days after fever onset, which is slightly prolonged compared with the median period of SARS-CoV-2 clearance previously reported.7–9 For the patients with COVID-19 who develop asthma exacerbation, it might be important to reduce the dose and duration of systemic corticosteroids as much as possible and administer drugs with antiviral abilities, such as favipiravir, in combination.

Information is limited on the epidemiology and management of asthma exacerbation associated with COVID-19, and further accumulation of evidence is required.

Acknowledgment

Because this study was a retrospective case report that only utilizes the data on medical charts and thoracic CT, the requirement for obtaining informed consent from the studied subject was waived by the Institutional Review Board.

This study was partially funded by Research Grant on Allergic Disease and Immunology from the Japan Agency for Medical Research and Development under grant number JP20ek0410055.

Conflict of interest

The authors have no conflict of interest to declare.

Yoshitaka Ono, Shohi Obayashi, Yukihiro Horio, Kyoko Niimi, Naoki Hayama, Yoko Ito, Tsuyoshi Oguma, Koichiro Asano

Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan

* Corresponding author. Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan.

E-mail address: ko-asano@tokai-u.jp (K. Asano).

References


Received 2 June 2020
Received in revised form 24 June 2020
Accepted 10 July 2020
Available online 27 July 2020